Updated Clinical Data from Combination of Margetuximab and Pembrolizumab in Gastric Cancer Presented at 2019 ASCO Gastrointestinal Cancers Symposium

“We continue to be very encouraged by the tolerability and antitumor activity of margetuximab with an anti-PD-1 mAb, an investigational, chemotherapy-free approach that is designed to coordinately engage innate and adaptive immunity for treatment of patients with advanced HER2+ gastric cancer,” said Scott Koenig, M.D., Ph.D., President and CEO of MacroGenics of new research presented at the 2019 ASCO Gastrointestinal Cancers Symposium.